MedPath

Evaluate the Safety and Efficacy of Modafinil in Children and Adolescents With ADHD

Phase 3
Completed
Conditions
Attention Deficit/Hyperactivity Disorder
ADHD
Registration Number
NCT00214981
Lead Sponsor
Cephalon
Brief Summary

Primary objective of this study is to evaluate the safety of treatment with modafinil film-coated tablet.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Patients are included in the study if they participated in a previous qualifying study with modafinil and, in the opinion of the investigator, will continue to benefit from treatment with modafinil. In addition, the following criteria must be met:

  • a boy or girl 6 to 17 years of age, inclusive, and English-speaking
  • weight and height between the 5th and 95th percentile on the National Center for Health Statistics (NCHS) growth chart for age, height, and weight
  • if more than 6 months since last dose of study drug, meets the full DSM-IV crieria for ADHD (combined typd, predominantly inattentive type, or predominantly hyperactive - impulsive type) at screening, as manifested by a psychiatric/clinical evaluation and confirmed by a structured diagnostic interview, namely, the Diagnostic Interview Schedule for Children, Fourth Edition (DISC-IV).
  • are in good health (except for a diagnosis of ADHD) as determined by medical and psychiatric history, physical examination, ECG, serum chemistry, hematology, urinalysis
  • girls of child bearing potential (Tanner scale >3) OR all girls 8 years of age and older have a negative urine pregnancy test at screening, must be using a medically acceptable method of birth control, and must agree to continue use of this method for the duration of the study (and for 30 days after participation in the study). (NOTE: For conducting pregnancy tests, the investigator has the option of determining the sexual maturity all girls 8 years of age and older.) Acceptable methods of birth control include: barrier method with spermicide; steroidal contraceptive (eg, oral, transdermal, implanted, and injected) in conjunction with a barrier method; intrauterine device (IUD); or abstinence
  • have a parent or legal guardian who is willing to participate in the study.
Exclusion Criteria

Patients are excluded from participating in this study if 1 or more of the following criteria are met:

  • a history or current diagnosis of pervasive developmental disorder, schizophrenia, or other psychotic disorders, or a clinical assessment of current suicide risk
  • any current psychiatric comorbidity, including but not limited to depression or other mood disorder, anxiety disorder, or pervasive mental disorder, that requires pharmacotherapy
  • a clinically significant drug sensitivity to stimulants such as amphetamine, dextroamphetamine, methylphenidate, pemoline
  • failure to respond to 2 or more adequate courses (dose or duration) of ADHD therapy
  • use of any other prescription medications for ADHD (e.g., amphetamine, dextroamphetamine, methylphenidate, pemoline, atomoxetine) after the screening visit
  • use of any MAO inhibitors or SSRIs within 2 weeks of the baseline visit
  • hypertension, defined as follows (SBP = systolic blood pressure and DBP = diastolic blood pressure):
  • ages 6-9 years SBP > 122mmHg or DBP>78mmHg
  • ages 10-12 years SBP > 126mmHg or DBP>82mmHg
  • ages 13-17 years SBP > 136mmHg or DBP>86mmHg
  • hypotension, defined as sitting systolic blood pressure (taken after resting for 5 minutes) of less than 50mmHg for children under 12 years of age or less than 80mmHg for children 12 and older
  • a sitting pulse outside the range of 60 through 115 bpm after resting for 5 minutes

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Evaluate the safety of treatment with the modafinil film coated tablet.
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (55)

UCI Child Development Center

🇺🇸

Irvine, California, United States

Marshfield Clinical Research

🇺🇸

Marshfield, Wisconsin, United States

Kentucky Pediatric/Adult Resea

🇺🇸

Bardstown, Kentucky, United States

Pedia Research, LLC

🇺🇸

Owensboro, Kentucky, United States

Dallas Pediatric Neurology

🇺🇸

Dallas, Texas, United States

CNS Research Institute PC

🇺🇸

Philadelphia, Pennsylvania, United States

NeuroScience, Inc.

🇺🇸

Bethesda, Maryland, United States

Miami Research Associates

🇺🇸

Miami, Florida, United States

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

Clinical Research Center of NV

🇺🇸

Las Vegas, Nevada, United States

Pacific Institute of Mental He

🇺🇸

Seattle, Washington, United States

Cientifica at Prarie View

🇺🇸

Newton, Kansas, United States

Vince and Associates Clinical

🇺🇸

Overland Park, Kansas, United States

University of Rochester

🇺🇸

Rochester, New York, United States

University of Alabama Birmingh

🇺🇸

Birmingham, Alabama, United States

University of CA San Francisco

🇺🇸

San Francisco, California, United States

Pahl Pharmaceutical Research

🇺🇸

Oklahoma City, Oklahoma, United States

University of Nebraska

🇺🇸

Omaha, Nebraska, United States

Summit Research Network Inc.

🇺🇸

Portland, Oregon, United States

Vanderbilt University Medical

🇺🇸

Nashville, Tennessee, United States

UT Health Science Center

🇺🇸

San Antonio, Texas, United States

Radiant Research Salt Lake

🇺🇸

Salt Lake City, Utah, United States

River Valley Neurology

🇺🇸

Fort Smith, Arkansas, United States

Clinical Neurophysiology Svcs

🇺🇸

Troy, Michigan, United States

Pivotal Research Center

🇺🇸

Mesa, Arizona, United States

CNS Research Institute

🇺🇸

Clementon, New Jersey, United States

Psychiatric Professional Servi

🇺🇸

Cincinnati, Ohio, United States

University of Buffalo

🇺🇸

Buffalo, New York, United States

Midwest Neurology, Inc.

🇺🇸

Danville, Indiana, United States

Children's Specialized Hospita

🇺🇸

Toms River, New Jersey, United States

New York Psychiatric Inst

🇺🇸

New York, New York, United States

Otter Creek Clinical Studies

🇺🇸

Burlington, Vermont, United States

Four Rivers Clinical Research

🇺🇸

Paducah, Kentucky, United States

Clinical Study Centers, LLC

🇺🇸

Little Rock, Arkansas, United States

BMR HealthQuest

🇺🇸

San Diego, California, United States

Amedica Research Inst.

🇺🇸

Hialeah, Florida, United States

Alpine Clinical Research

🇺🇸

Boulder, Colorado, United States

Encompass Clinical Research

🇺🇸

Spring Valley, California, United States

Child Neurology Assoc.

🇺🇸

Atlanta, Georgia, United States

Mountainview Center for Resear

🇺🇸

Decatur, Georgia, United States

Clinical Neuroscience Solution

🇺🇸

Memphis, Tennessee, United States

Children's Developmental Cente

🇺🇸

Maitland, Florida, United States

Foothills Psychiatry

🇺🇸

Boise, Idaho, United States

Consultants in Neurology, Ltd.

🇺🇸

Northbrook, Illinois, United States

Radiant Research Las Vegas

🇺🇸

Las Vegas, Nevada, United States

OCCI Eugene

🇺🇸

Eugene, Oregon, United States

North Carolina Neuropsychiatry

🇺🇸

Charlotte, North Carolina, United States

OCCI, Inc.

🇺🇸

Salem, Oregon, United States

Primary Physicians Research

🇺🇸

Pittsburgh, Pennsylvania, United States

Monarch Research Associates

🇺🇸

Norfolk, Virginia, United States

James A. Knutson, MD

🇺🇸

Kirkland, Washington, United States

Sarkis Clinical Trials

🇺🇸

Gainesville, Florida, United States

Dolby Providers, Inc.

🇺🇸

New Orleans, Louisiana, United States

Michael J. Rieser, MD

🇺🇸

Lexington, Kentucky, United States

Rhode Island Hospital

🇺🇸

Providence, Rhode Island, United States

© Copyright 2025. All Rights Reserved by MedPath